Robert E. Reiter, MD

Academic/Professional Titles

Professor, Urology, Molecular Biology,
Director of the Prostate Cancer Program
Director of Urologic Research
Co-Director of the Genitourinary Oncology Program in UCLA's Jonsson Cancer Center

Bio

Dr. Reiter is the Bing Professor of Urologic Oncology, Chief of the Division of Urologic Oncology, and Director of UCLA's prostate cancer program. He attended Stanford Medical School, completed his urologic training at Stanford and Baylor College of Medicine, and completed additional fellowship training in urological cancer at the National Cancer Institute. Dr. Reiter was awarded the Outstanding Achievement Award by the Urologic Oncology branch of the National Cancer Institute.

Dr. Reiter is an internationally recognized expert in all areas of prostate cancer management and research. He was among the first to integrate functional MRI imaging and PSMA PET imaging into the diagnosis, surgical management, and care of men with prostate cancer. He was also an early innovator in the field of robotic surgery, and has completed more than 2,500 robotic prostatectomies. In addition to surgical management of prostate cancer, Dr. Reiter has expertise in MRI-guided biopsies to diagnose prostate cancer, focal therapy to treat select individuals, as well as all forms of medical therapy. Dr. Reiter has a particular interest in the multidisciplinary management of men with high-risk prostate cancer, incorporating the latest in genomics, clinical trials, and precision medical therapies into treatment plans in collaboration with UCLA leaders in the areas of radiation, medical and nuclear prostate oncology.

In addition to his broad clinical interests in prostate cancer, Dr. Reiter is a leading researcher in prostate cancer and has led UCLA’s 12 million SPORE grant, which supports work to translate laboratory discoveries into clinical advances, for more than 15 years. Drugs such as enzalutamide and apalutamide, and imaging tools such as PSMA PET, are among the many advances that have emanated from this program. His own laboratory discovered the prostate stem cell antigen and developed antibodies to target this protein, which has led to novel imaging and therapeutic approaches for prostate cancer currently in clinical trials. Dr. Reiter has authored more than 250 papers and lectures nationally and internationally on all aspects of clinical care of men with prostate cancer.